Startup: Abridge
Recommended by: Marisa Bass, Primary Venture Partners; Shravan Narayen, IVP; Deena Shakir, Lux Capital
Relationship: Primary and Lux have no financial interest in Abridge. IVP is an investor in Abridge.
Total funding: $212.5 million
What it does: Abridge’s generative AI tech transcribes patient-doctor interactions and documents those visits in electronic health records.
Why it’s on the list: Abridge raised a $150 million Series C round in February to keep developing its tech and relieve administrative burdens from clinicians as healthcare’s labor crisis continues. Narayen and Bass highlighted Abridge’s partnership with EHR giant Epic, which could help the startup gain more traction with hospitals this year.
“Abridge has a lot of the necessary ingredients (capital, early commercial traction, strong ecosystem partners, high caliber team) to support provider workflows, help improve communication with patients while also serving as a scaled GenAI business, that could spur additional investment in the space,” Bass said.
Shakir said she’s “been amazed at the progress the company has made to date,” noting its partnerships with major health systems including Yale New Haven Health, UChicago Medicine, and Sutter Health — and “most importantly, doctors seem to love the product!”